Teneobio will utilize Selexis’ proprietary SUREtechnology Platform™ to develop research cell banks (RCBs) for three additional preclinical candidates for the potential treatments of B-cell malignan...
Industry Experts to Provide Strategic Guidance as the Companies Advance Technologies Used in the Discovery, Analytics and Manufacturing of Difficult-to-Express Biologics
Selexis SA has been appointed for cell line development. KBI Biopharma, Inc. has been appointed for process development, analytical development, formulation development, and clinical manufacturing ...
Paper in Frontiers in Immunology Describes Trimer Design and Development of Production CHO Cell Lines That Generate Properly Folded HIV-1 Env Trimers to Support Goal of Developing an Effective HIV ...